Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

Key Takeaways Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Teva Pharmaceutical Industries Ltd is a global leader in the pharmaceutical industry, specializing in the development, manufacture, and distribution of generic and specialty medicines, as well as ...

Teva CEO Richard Francis said that he had not expected such a harsh reaction from the market but he sees a positive side to ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 15.0% during the 4th quarter, according to its most ...

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for ...

Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, analysts forecast that Teva Pharmaceutical Industries will post 2.62 EPS ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...